26.03
price up icon0.58%   +0.15
after-market  After Hours:  26.015  -0.015   -0.06%
loading
Genmab ADR stock is currently priced at $26.03, with a 24-hour trading volume of 571.80K. It has seen a +0.58% increased in the last 24 hours and a -10.70% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $25.79 pivot point. If it approaches the $26.04 resistance level, significant changes may occur.
Previous Close:
$25.88
Open:
$26.03
24h Volume:
571.80K
Market Cap:
$16.65B
Revenue:
$2.58B
Net Income/Loss:
$794.60M
P/E Ratio:
25.97
EPS:
1.0022
Net Cash Flow:
$781.65M
1W Performance:
-0.61%
1M Performance:
-10.70%
6M Performance:
-16.22%
1Y Performance:
-31.86%
1D Range:
Value
$25.77
$26.05
52W Range:
Value
$25.38
$42.72

Genmab ADR Stock (GMAB) Company Profile

Name
Name
Genmab ADR
Name
Phone
45 70 20 27 28
Name
Address
Kalvebod Brygge 43, Copenhagen
Name
Employee
419
Name
Twitter
@Genmab
Name
Next Earnings Date
2024-06-03
Name
Latest SEC Filings
Name
GMAB's Discussions on Twitter

Genmab ADR Stock (GMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-23-24 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-22-24 Downgrade Citigroup Neutral → Sell
Dec-06-23 Upgrade UBS Neutral → Buy
Nov-10-23 Upgrade Deutsche Bank Hold → Buy
Nov-08-23 Upgrade DNB Markets Sell → Buy
Oct-18-23 Initiated Exane BNP Paribas Underperform
Sep-06-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-24-23 Initiated BTIG Research Buy
Jul-14-23 Initiated HSBC Securities Buy
May-31-23 Initiated UBS Neutral
May-12-23 Initiated Morgan Stanley Underweight
Dec-20-22 Downgrade Citigroup Buy → Neutral
Nov-14-22 Initiated William Blair Mkt Perform
Nov-11-22 Downgrade Deutsche Bank Buy → Hold
Jun-24-22 Initiated BMO Capital Markets Market Perform
May-02-22 Initiated Cowen Market Perform
Mar-16-22 Upgrade UBS Neutral → Buy
Jan-31-22 Upgrade H.C. Wainwright Neutral → Buy
Jan-03-22 Downgrade Guggenheim Buy → Neutral
Dec-01-21 Initiated Berenberg Sell
Sep-16-21 Downgrade Jefferies Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-24-21 Downgrade H.C. Wainwright Buy → Neutral
Apr-20-21 Initiated Deutsche Bank Buy
Jan-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-20 Downgrade Bryan Garnier Neutral → Sell
Sep-08-20 Initiated SVB Leerink Mkt Perform
Jun-25-20 Downgrade Credit Suisse Outperform → Neutral
Apr-23-20 Initiated Credit Suisse Outperform
Feb-24-20 Reiterated H.C. Wainwright Buy
Jan-13-20 Initiated SunTrust Buy
Dec-12-19 Downgrade Deutsche Bank Buy → Hold
Sep-13-19 Upgrade BofA/Merrill Neutral → Buy
Sep-12-19 Upgrade JP Morgan Neutral → Overweight
Aug-12-19 Initiated Guggenheim Buy
Aug-12-19 Initiated Morgan Stanley Overweight
Aug-12-19 Initiated RBC Capital Mkts Outperform
View All

Genmab ADR Stock (GMAB) Financials Data

Genmab ADR (GMAB) Revenue 2024

GMAB reported a revenue (TTM) of $2.58 billion for the quarter ending March 31, 2024, a +21.88% rise year-over-year.
loading

Genmab ADR (GMAB) Net Income 2024

GMAB net income (TTM) was $794.60 million for the quarter ending March 31, 2024, a +10.17% increase year-over-year.
loading

Genmab ADR (GMAB) Cash Flow 2024

GMAB recorded a free cash flow (TTM) of $781.65 million for the quarter ending March 31, 2024, a -11.30% decrease year-over-year.
loading

Genmab ADR (GMAB) Earnings per Share 2024

GMAB earnings per share (TTM) was $1.2067 for the quarter ending March 31, 2024, a +10.37% growth year-over-year.
loading
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
$156.11
price up icon 0.37%
$83.78
price down icon 1.10%
$84.64
price down icon 1.44%
$165.70
price up icon 5.27%
$394.47
price up icon 1.70%
Cap:     |  Volume (24h):